Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics and Econometrics,General Medicine
Reference63 articles.
1. European Medicines Agency. Vitrakvi larotrectinib; 2019. https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf [Accessed 26 Sep 2019].
2. Yates LR, Seoane J, Le Tourneau C, et al. The European Society for Medical Oncology (ESMO) precision medicine glossary. Ann Oncol. 2018;29(1):30–5.
3. Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895–902.
4. Cooper S, Bouvy JC, Baker L, et al. How should we assess the clinical and cost effectiveness of histology independent cancer drugs? BMJ. 2020;368:I6435.
5. Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg (verdiepingsmodules); 2016. https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg [Accessed 5 Jan 2018].
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献